Pascal Biosciences
  • Home
  • About Us
    • About
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • Cannabinoid therapeutic for treating COVID-19
    • PAS-403 for Glioblastoma
    • PAS-393 for Cancer
    • Research: Pre-BCR antibody for Leukemia
  • News
  • Investors
  • Contact
Skip to content

11Sep 2019

Pascal Biosciences to Present at International Cannabinoid Derived Pharmaceuticals Summit

  • Sep 11, 2019
  • Press Releases

VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, Sept 11, 2019 –Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”). Pascal announces that Dr. Patrick Gray, CEO, will present an update today on the Company’s lead cannabinoid-based drug candidate, PAS-403, at the Second…

Read More

29May 2019

Pascal Biosciences to Present at 2019 BIO International Convention

  • May 29, 2019
  • Press Releases

VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, May 29, 2019 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the company will present at the upcoming BIO International Convention taking place June 3-6…

Read More

8May 2019

Pascal Biosciences Announces Formation of Clinical Advisory Board

  • May 8, 2019
  • Press Releases

Pascal Biosciences Announces Formation of Clinical Advisory Board  Preeminent Neuro-Oncology Experts to Guide PAS-403 Development Efforts VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, May 8, 2019 – Pascal Biosciences Inc. (TSX.V:PAS)(“Pascal” or the “Company”), a drug discovery and development company, today…

Read More

23Apr 2019

Pascal Biosciences Provides Corporate Update for First Quarter of 2019

  • Apr 23, 2019
  • Press Releases

VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, April 23, 2019 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today provided a corporate update for the first quarter of 2019. “We’ve made significant strides since…

Read More

1Apr 2019

Pascal Biosciences names Carl Weissman acting President

  • Apr 1, 2019
  • Press Releases

VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, April 1, 2019 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced that Carl Weissman has joined the company in the role of acting President. Weissman…

Read More

18Mar 2019

Pascal Biosciences Partners with Mitacs to Support Innovative Cancer Research at University of British Columbia

  • Mar 18, 2019
  • Press Releases

VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, March 18, 2019 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced a partnership with Mitacs for a multi-year cancer research project at the University of…

Read More

24Jan 2019

Pascal Biosciences Commences Cannabinoid Testing of Human Volunteers and Patients

  • Jan 24, 2019
  • Press Releases

VANCOUVER, British Columbia, and SEATTLE, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the testing of cannabinoids in human subjects for its immune stimulatory program in cancer. Furthermore,…

Read More

28Dec 2018

Pascal Biosciences Provides Year-End Investor Update and Reviews Upcoming Milestones

  • Dec 28, 2018
  • Press Releases

- 2018 pipeline expansion includes lead cannabinoid-based cancer therapeutic - Clinical trial in glioblastoma to begin in 2019 VANCOUVER, British Columbia and SEATTLE, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development…

Read More

11Dec 2018

Pascal Biosciences Announces Year-End Investor Update Webcast

  • Dec 11, 2018
  • Press Releases

Advancement of Cannabinoid Cancer Programs and Corporate Review to be Presented Scheduled for Dec. 17, 2018 at 1:30 p.m. Pacific VANCOUVER, British Columbia and SEATTLE, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug…

Read More

28Nov 2018

Pascal Biosciences Expands Leadership Team to Support Strategic Advancement of Its Cannabinoid Based Programs

  • Nov 28, 2018
  • Press Releases

VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, November 28, 2018 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the strengthening of its leadership team with the appointments of seasoned executives in therapeutic…

Read More

Page Navigation

  • Previous
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • Next

Recent Posts

  • Pascal Biosciences Signs Term Sheet for Acquisition of THC Essentials
  • PASCAL BIOSCIENCES PLANS NEW DIRECTION TO INCLUDE CONTRACT RESEARCH
  • Pascal Biosciences First To File Patent For COVID-19 Antiviral Activity With CBD
  • Pascal Biosciences Sign Term Sheet for $2,000,000 Convertible Notes
  • Pascal Biosciences Settles Certain Outstanding Payables with Issuance of Shares and Details Share-related Compensation to Employees

Categories

  • In the News
  • Press Releases
  • Uncategorized

Archives

  • December 2022
  • June 2022
  • April 2022
  • March 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • June 2021
  • March 2021
  • January 2021
  • December 2020
  • November 2020
  • September 2020
  • August 2020
  • July 2020
  • May 2020
  • March 2020
  • October 2019
  • September 2019
  • May 2019
  • April 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • July 2018
  • June 2018
  • February 2018
  • December 2017
  • September 2017
  • May 2017
  • March 2017
  • November 2016
  • October 2016
  • September 2016

About

Pascal Biosciences Inc. (TSX-V: PAS, FSE:6PB.F, OTC:PSCBF) is a biotechnology company focused on developing cannabinoid-based and targeted therapeutics to fight cancer.

Locations

USA

Fluke Hall, Suite 304
Box 352141
4000 Mason Road
Seattle, WA 98195-2141

Canada

280 7th Avenue East
Vancouver, BC V5T 0B4

Contact

Phone

206.221.3443

Email

info@pascalbiosciences.com

Investors

invest@pascalbiosciences.com

Partnering & Business Development

bd@pascalbiosciences.com

Let's Connect

  • Facebook
  • Twitter
  • Linked
  • Home
  • Company
  • Programs
  • News
  • Investors
  • Contact
  • Disclaimer
  • Legal Notices

© Copyright 2023 Pascal Biosciences Inc. All rights reserved.   Seattle Website Design by Jordan Crown Design

  • Home
  • About Us
    • About
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • Cannabinoid therapeutic for treating COVID-19
    • PAS-403 for Glioblastoma
    • PAS-393 for Cancer
    • Research: Pre-BCR antibody for Leukemia
  • News
  • Investors
  • Contact

‹ › ×